Navigation Links
BioMS Medical Announces Third Quarter 2008 Results
Date:11/6/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 6 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the third quarter ended September 30, 2008. BioMS Medical, in partnership with Eli Lilly and Company (Lilly), is developing dirucotide (MBP8298), a drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the U.S.

"The third quarter saw positive developments in the dirucotide development plan, with completion of the interim analysis resulting in a significant milestone payment from our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "Dirucotide was also granted fast track designation by the U.S. FDA, another important achievement which could potentially accelerate the development and review process for this important MS drug."

Currently, BioMS is conducting three clinical trials and one open-label follow-on trial for dirucotide (MBP8298):

- MAESTRO-01: A randomized, double-blind pivotal phase II/III trial in

Canada and Europe evaluating dirucotide (MBP8298) for the treatment

of secondary progressive MS (SPMS). The study has completed full

recruitment of 611 patients at 47 trial sites in 9 countries. To

date, there have been nine positive safety reviews from the Data

Safety Monitoring Board (DSMB). Full analysis of this trial is

expected in the second half of 2009.

- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal

trial. Eligible patients who have successfully completed the blinded,

placebo controlled MAESTRO-01 trial may choose to receive dirucotide

(MBP8298) on an un-blinded basis. To date, approximately 95% of

patients enrolled in MAESTRO-01 have proceeded to MAESTRO-02.

- MAESTRO-03: A U.S. pivotal phase III trial evaluatin
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Culver City, CA (PRWEB) May 20, 2013 ... Trustees has announced the appointment of Lisa Baird as ... WMIS on July 8, 2013. The WMIS ... multi-modal imaging applications to understand and effectively treat diseases ... Molecular Imaging Society (WMIS) was established in 2011 by ...
(Date:5/17/2013)... Dr. Sparano is Professor of Medicine ... the Albert Einstein College of Medicine and Associate Chairman ... Center. He is also Associate Director for Clinical ... Einstein Breast Cancer Working Group, a multidisciplinary group of ... He also serves as Vice Chair of the National ...
(Date:5/17/2013)... Elsevier, a world-leading provider of scientific, technical and medical ... a recent study in Reproductive BioMedicine Online ... those with an abnormal chromosomal composition can be identified ... blastocysts, thereby classifying the risk of genetic abnormality without ... has undertaken a retrospective study, using their predictive model ...
(Date:5/17/2013)... ALTO, Calif. , May 17, 2013 /PRNewswire/ ... it has achieved 50% enrollment of the total ... to evaluate the safety and preliminary efficacy of ... Cells) therapy for Knee Osteoarthritis (KOA). To date ... (SAE) reported. The Phase I open ...
Breaking Biology Technology:WMIS Appoints Lisa Baird as Next Executive Director 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 2Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group 3Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2
... Technology Development for the Conversion of Biomass to ... Netherlands, November 1, Khosla Ventures and BIOeCON announce ... Khosla Ventures, will provide the Series A,funding, whereas ... the ,Biomass Catalytic Cracking Process, (BCC). KiOR Inc. ...
... 1 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President,and CEO of ... a,corporate overview of the Company at the Acumen BioFin ... 6, 2007 at 3:20 p.m. ET.,The event will be ... 5-7,2007. A live audio webcast of the presentation ...
... the Most Advanced ... Bio-Science Imaging Protocols, MELVILLE, N.Y., Nov. ... launch of its latest,inverted microscope series, the Eclipse Ti. Available ... flexibility and efficient,multi-mode microscopy as part of a fully-integrated microscope ...
Cached Biology Technology:Khosla Ventures and BIOeCON Form KiOR Inc. 2Khosla Ventures and BIOeCON Form KiOR Inc. 3Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Nikon Unveils the Eclipse Ti Inverted Microscope Series at The Society for Neroscience Annual Meeting 2Nikon Unveils the Eclipse Ti Inverted Microscope Series at The Society for Neroscience Annual Meeting 3
(Date:5/17/2013)... Atlanta residents of all ages will celebrate the ... impact on our daily lives during the inaugural ... engineers and educators from local museums, corporations, K-12 ... than 40 different events for children and adults ... http://atlantasciencefestival.org . , The annual Atlanta ...
(Date:5/17/2013)... The iCargo project (Intelligent Cargo in Efficient and Sustainable ... thanks to an improvement in the efficiency of intermodal ... assist decision making. It comprises 29 European organisations with ... management. It has a budget totalling 17,000,000 and a ... is working to specify and develop the semantic components ...
(Date:5/17/2013)... An international team of scientists ... and cell movement inside a living frog embryo in ... new method to advance biological research and the search ... University and the Karlsruher Institut fr Technologie in Germany, ... U.S. Department of Energy,s Argonne National Laboratory, released the ...
Breaking Biology News(10 mins):First Atlanta Science Festival set for 2014 2New logistics services that will cut energy consumption and CO2 emissions 2New X-ray method shows how frog embryos could help thwart disease 2
... Service (MMS) and National Oceanographic and Atmospheric Administration (NOAA) ... about the prey of sperm whales in the northern ... three legs was completed on February 10, 2010 and ... legs of the cruise departed from the NOAA Fisheries ...
... last year as a possible "missing link" between humans and ... lorises, according to two papers by scientists at The University ... Chicago. In an article now available online in the ... that the 47-million-year-old Darwinius masillae is not a ...
... Following an intense study of agricultural ecosystems ... simultaneous analysis and management of a wide range ... Raudsepp-Hearne of McGill University,s Department of Geography, Elena ... Garry Peterson of the Stockholm Resilience Centre at ...
Cached Biology News:MMS and NOAA scientists study prey of Gulf of Mexico sperm whales 2Recently analyzed fossil was not human ancestor as claimed, anthropologists say 2Recently analyzed fossil was not human ancestor as claimed, anthropologists say 3Seeing the hidden services of nature 2
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
Neutrophil cytosol factor 2 (NCF-2) (Neutrophil NADPH oxidase factor 2) (67 kDa neutrophil oxidase factor) (p67-phox) (NOXA2). [Source:Uniprot/SWISSPROT;Acc:P19878] Antigen: Recombinant Protein E...
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Biology Products: